Alkermes Plc (ALKS) is a global biopharmaceutical company committed to developing innovative medicines to improve the lives of patients suffering from serious chronic conditions. Founded in 1987, the Dublin, Ireland-based company has operational headquarters in Waltham, Massachusetts. Alkermes specializes in developing treatments in the areas of mental health, addiction, schizophrenia, and oncology.
One of the company's core beliefs is that drug delivery technologies can significantly improve the effectiveness and safety of different types of drugs, enabling better patient outcomes. Alkermes has developed many proprietary, clinically meaningful advances in drug delivery technologies, which have led to the development of therapies with improved attributes and outcomes.
The company's rich pipeline of drug candidates includes both commercial products and advanced clinical development programs. These products are designed to address unmet medical needs of patients in major therapeutic areas including schizophrenia, depression, opioid dependence, alcohol dependence, and multiple sclerosis, among others.
Some of the company's notable products include ARISTADA® (for schizophrenia), VIVITROL® (for alcohol and opioid dependence), and LYBALVI™ (for schizophrenia and bipolar I disorder). Moreover, Alkermes has several collaborative arrangements with some of the world's leading pharmaceutical companies such as Amgen, Biogen, and Johnson & Johnson.
The company's business model combines proprietary technologies, sophisticated research and development capabilities, and expertise in manufacturing and commercialization. Alkermes' strategy is centered on maximizing the value of the portfolio through a combination of advancing the pipeline, optimizing the profitable products, and leveraging the capabilities to drive long-term growth.
Alkermes employs approximately 2,400 people worldwide and prides itself on a company culture that encourages innovation, collaboration, and the pursuit of scientific excellence. Their goal is to translate advances in science and technology into therapies that help patients regain valuable aspects of their lives that were lost due to illness. It is guided by its responsibility to patients, employees, and shareholders in everything it does.
In recent years, Alkermes is increasing its focus on research and development and investing in new technologies and treatments, in line with its commitment to making a lasting impact on global health. Despite facing challenges in the biopharmaceutical industry, the company has proven its resilience and continues to be a recognized leader in its field. In summary, Alkermes Plc is a company committed to transforming lives through science, driven by its passion for innovation and the need to make a substantial, positive impact on healthcare outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alkermes reported early positive results for its investigational oral ADHD drug, ALKS 7290, showing symptom improvements in a small Phase 1b trial. While these initial findings support further development, the study was not powered to establish statistical significance over placebo. The company plans a larger Phase 2 trial with results expected in 2027 to determine efficacy and tolerability compared to placebo.
Amundi significantly increased its stake in Alkermes plc (NASDAQ:ALKS) during the first quarter, nearly doubling its holdings to 64,710 shares valued at approximately $2.29 million. Institutional investors now own 95.21% of the company's stock, which trades between a 52-week low of $25.17 and a high of $55.67. Analysts have a "Moderate Buy" consensus rating with an average price target of $54.56, while recent insider transactions show executives selling shares totaling around $3.9 million over the past 90 days.
This article provides an AI-driven analysis of Alkermes Plc (NASDAQ: ALKS), focusing on risk channels and responsive allocation strategies. It highlights strong near-term sentiment with a potential shift to long-term positive bias, noting a significant risk-reward short setup. The analysis outlines three specific trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles.